Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.

The oncologist - 1 Jan 2018

Ciombor Kristen K, Bekaii-Saab Tanios

Abstract excerpt

The emergence of targeted therapies for the treatment of metastatic colorectal cancer (mCRC) has considerably improved survival, but has also resulted in a dilemma of identifying the optimal sequence and combination of various agents in the mCRC treatment landscape. A number of cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil, capecitabine, and TAS-102, are available for treatment of mCRC....

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Colorectal Neoplasms
High-Throughput Nucleotide Sequencing
Liver Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 29021377
DOI: 10.1634/theoncologist.2017-0203
PMCID: PMC5759820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.PMID 29021377Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Current perspectives on the treatment of BRAF mutated colorectal carcinoma.Semantic proximity Read ↗

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Updates in the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Metastatic colorectal cancer: current state and future directions.Semantic proximity Read ↗

Update on Emerging Therapies for Advanced Colorectal Cancer.Semantic proximity Read ↗

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.